Visit the ACCC COVID-19 Resource Center & Listserv for Insights on Providing Optimal Patient Care During the Pandemic.



In This Section

Home / Blurb / Discussion List

FDA Approves Kyprolis Once-Weekly Dosing Option for Multiple Myeloma

Oct 31, 2018, 11:13 AM
On October 1, the FDA approved the supplemental New Drug Application (sNDA) to expand the Prescribing Information for Kyprolis (carfilzomib) to include a once-weekly dosing option in combination with dexamethasone (once-weekly Kd70) for patients with relapsed or refractory multiple myeloma.

Read the full Amgen press release here.

Posted 10/31/2018

Leave a comment